“Results from a phase II trial conducted by Biogen Idec demonstrated that galiximab may be used as an adjunct to Rituxan to produce a combination with the potential to prolong survival in follicular non-Hodgkin’s lymphoma.

“The data indicates that the combination treatment provides longer event-free survival (EFS) in patients with relapsed or refractory non-Hodgkin’s lymphoma (NHL) when compared to previous results with Rituxan monotherapy. Side effects of the combination were similar to treatment with Rituxan alone.”

Read more at Biogen proves drug combo slows cancer

Recent Entries

• Sigma Pharmaceuticals year profit rises 27 pct
• South African citizens cheap drug guinea pigs
• Two drugs test victims face a year in coma
• Can drug companies improve their reputation?
• Pfizer Sees 40 Percent Rise in 2006 Net on Cost Cuts
• Pfizer’s Forecast Disappoints
• Pharmaceutical RFID Adoption Stalls
• Inhalable Drug Might Bring Sigh Of Relief To Diabetes Patients
• GlaxoSmithKline unveils best results since merger
• Pfizer Sues Teva, Sandoz Over Zithromax

This entry was posted on Friday, June 17th, 2005 at 2:51 am and is filed under General. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.